What is XCR Diagnostics?
XCR Diagnostics is at the forefront of molecular diagnostics, developing innovative testing solutions designed for speed and accessibility. Their proprietary Xtreme Chain Reaction technology is central to enhancing nucleic acid amplification, thereby streamlining diagnostic processes. The company's mission is to elevate healthcare quality by providing cost-effective, portable testing systems suitable for near-patient applications. Their primary clientele includes healthcare providers and organizations requiring rapid and dependable infectious disease detection capabilities.
How much funding has XCR Diagnostics raised?
XCR Diagnostics has raised a total of $398K across 2 funding rounds:
Debt
$150K
Debt
$248K
Debt (2020): $150K with participation from PPP
Debt (2021): $248K led by PPP
What's next for XCR Diagnostics?
With the recent influx of capital and its classification as a large-scale late-stage funding event, XCR Diagnostics is poised for significant expansion and market penetration. This strategic investment likely signals a phase of scaling operations, further research and development, and potentially broader commercialization of their advanced diagnostic technologies. The company's focus on efficiency and affordability in infectious disease testing positions it well to address critical healthcare needs, especially in decentralized testing environments.
See full XCR Diagnostics company page
